PLA2G7 and eye disorder: Importantly, these findings also support that Lp‐PLA2 inhibitors, such as darapladib, might be valuable in eye diseases characterized by vascular abnormalities.36 Additionally, our group reported a novel Lp‐PLA2 inhibitor that could inhibit retinal thickening in STZ‐induced diabetic SD rats after oral dosing for 4 weeks, and further comprehensive studies are currently underway.194